Patents by Inventor Jorgen Wittendorff
Jorgen Wittendorff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10456389Abstract: The invention provides various extended release granules of nicotinamide. Granule properties can be enhanced by the inclusion of a conductive filler.Type: GrantFiled: June 13, 2014Date of Patent: October 29, 2019Assignee: CONARIS RESEARCH INSTITUTE AGInventors: Bent Højgaard, Jørgen Wittendorff
-
Patent number: 10307459Abstract: Good bioavailability of desmopressin can be obtained with an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.Type: GrantFiled: January 26, 2018Date of Patent: June 4, 2019Assignee: FERRING B.V.Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
-
Publication number: 20180280469Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.Type: ApplicationFiled: January 26, 2018Publication date: October 4, 2018Applicant: Ferring B.V.Inventors: Anders NILSSON, Hans LINDNER, Jørgen WITTENDORFF
-
Patent number: 9919025Abstract: Described herein are orodispersible pharmaceutical dosage forms of desmopressin comprising desmopressin free base or a pharmaceutically acceptable salt thereof, and one or more carriers, wherein at least one carrier is hydrolyzed gelatin in an open matrix network structure. Also described are methods of making and using such desmopressin orodispersible pharmaceutical dosage forms.Type: GrantFiled: October 25, 2016Date of Patent: March 20, 2018Assignee: FERRING B.V.Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
-
Publication number: 20170112895Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.Type: ApplicationFiled: October 25, 2016Publication date: April 27, 2017Applicant: Ferring B.V.Inventors: Anders NILSSON, Hans LINDNER, Jørgen WITTENDORFF
-
Patent number: 9504647Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.Type: GrantFiled: November 20, 2015Date of Patent: November 29, 2016Assignee: FERRING B.V.Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
-
Publication number: 20160175246Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.Type: ApplicationFiled: November 20, 2015Publication date: June 23, 2016Applicant: Ferring B.V.Inventors: Anders NILSSON, Hans LINDNER, Jørgen WITTENDORFF
-
Publication number: 20160136147Abstract: The invention provides various extended release granules of nicotinamide. Granule properties can be enhanced by the inclusion of a conductive filler.Type: ApplicationFiled: June 13, 2014Publication date: May 19, 2016Applicant: Ferring B.V.Inventors: Bent Højgaard, Jørgen WITTENDORFF
-
Patent number: 9114083Abstract: Disclosed are improved granular pharmaceutical preparations, together with improved methods and apparatus for preparation of granules for use in such preparations. Such methods are especially useful for making granules for solid oral dose pharmaceutical preparations, and are particularly suited to the production of granules comprising 5-aminosalicylic acid (5-ASA) for the treatment of inflammatory bowel disease. The granules exhibit a more sharply peaked length distribution, and hence aspect ratio distribution, and have a consequently much sharper dissolution profile after further processing.Type: GrantFiled: May 16, 2014Date of Patent: August 25, 2015Assignee: FERRING B.V.Inventors: Carsten Hoeg-Moller, Crilles Casper Larsen, Jorgen Wittendorff, Birgitte Nissen, Kenneth Manby Pedersen, Tue Hansen, Helle Poulsen
-
Publication number: 20150150938Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.Type: ApplicationFiled: July 9, 2014Publication date: June 4, 2015Applicant: Ferring BVInventors: Anders Nilsson, Hans LINDNER, Jørgen WITTENDORFF
-
Publication number: 20140328934Abstract: Disclosed are improved granular pharmaceutical preparations, together with improved methods and apparatus for preparation of granules for use in such preparations. Such methods are especially useful for making granules for solid oral dose pharmaceutical preparations, and are particularly suited to the production of granules comprising 5-aminosalicylic acid (5-ASA) for the treatment of inflammatory bowel disease. The granules exhibit a more sharply peaked length distribution, and hence aspect ratio distribution, and have a consequently much sharper dissolution profile after further processing.Type: ApplicationFiled: May 16, 2014Publication date: November 6, 2014Applicant: Ferring B.V.Inventors: Carsten Hoeg-Moller, Crilles Casper Larsen, Jorgen Wittendorff, Birgitte Nissen, Kenneth Manby Pedersen, Tue Hansen, Helle Poulsen
-
Patent number: 8802624Abstract: Described herein are methods of treating diseases or conditions such as incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus, by administering desmopressin acetate in an orodispersiblc solid dosage form that disintegrates in the mouth within 10 seconds and includes an amount of desmopressin acetate, measured as the free base, of from 10 to 600 ?g.Type: GrantFiled: May 18, 2011Date of Patent: August 12, 2014Assignee: Ferring B.V.Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
-
Patent number: 8765185Abstract: Disclosed are improved granular pharmaceutical preparations, together with improved methods and apparatus for preparation of granules for use in such preparations. Such methods are especially useful for making granules for solid oral dose pharmaceutical preparations, and are particularly suited to the production of granules comprising 5-aminosalicylic acid (5-ASA) for the treatment of inflammatory bowel disease. The granules exhibit a more sharply peaked length distribution, and hence aspect ratio distribution, and have a consequently much sharper dissolution profile after further processing.Type: GrantFiled: December 15, 2010Date of Patent: July 1, 2014Assignee: Ferring B.V.Inventors: Carsten Hoeg-Moller, Crilles Casper Larsen, Jorgen Wittendorff, Birgitte Nissen, Kenneth Manby Pedersen, Tue Hansen, Helle Poulsen
-
Publication number: 20130022681Abstract: Disclosed are improved granular pharmaceutical preparations, together with improved methods and apparatus for preparation of granules for use in such preparations. Such methods are especially useful for making granules for solid oral dose pharmaceutical preparations, and are particularly suited to the production of granules comprising 5-aminosalicylic acid (5-ASA) for the treatment of inflammatory bowel disease. The granules exhibit a more sharply peaked length distribution, and hence aspect ratio distribution, and have a consequently much sharper dissolution profile after further processing.Type: ApplicationFiled: December 15, 2010Publication date: January 24, 2013Applicant: Ferring B.V.Inventors: Carsten Hoeg-Moller, Crilles Casper Larsen, Jorgen Wittendorff, Birgitte Nissen, Kenneth Manby Pedersen, Tue Hansen, Helle Poulsen
-
Publication number: 20120071538Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.Type: ApplicationFiled: May 18, 2011Publication date: March 22, 2012Inventors: Anders Nilsson, Hans Lindner, JØRGEN Wittendorff
-
Patent number: 7947654Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.Type: GrantFiled: June 18, 2009Date of Patent: May 24, 2011Assignee: Ferring B.V.Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
-
Publication number: 20090318665Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.Type: ApplicationFiled: June 18, 2009Publication date: December 24, 2009Inventors: Anders Nilsson, Hans Lindner, Jorgen Wittendorff
-
Patent number: 7560429Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.Type: GrantFiled: May 7, 2003Date of Patent: July 14, 2009Assignee: Ferring B.V.Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
-
Publication number: 20050232997Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.Type: ApplicationFiled: May 7, 2003Publication date: October 20, 2005Inventors: Andres Nilsson, Hans Lindner, Jorgen Wittendorff